Wilson Disease Clinical Trials
We are no longer recruiting for Phase 2. Check back for information about a Phase 3 Study with WTX-101
Phase 2 Study in Newly Diagnosed Wilson Disease Patients with WTX101 (Tetrathiomolybdate)
Patients are being recruited for a Phase 2, multi-center, open-label, study to evaluate the efficacy and safety of WTX101 administered for 24 weeks in newly diagnosed Wilson Disease patients. This study is being sponsored by Wilson Therapeutics.
The study drug, WTX101 (bis-choline tetrathiomolybdate) is a de-coppering agent that is being investigated for the treatment of Wilson Disease. The aim of this study is to confirm that the dosing regimen planned for use in future studies with WTX101 is safe and effective in de-coppering newly diagnosed Wilson Disease patients. The study will be conducted at 6 Wilson Disease expert centers (University of Michigan Hospital, Ann Arbor, MI; Yale University Medical Center, New Haven, CT; UCLA Ronald Reagan Medical Center, Los Angeles, CA; Medical University of Vienna, Vienna, Austria; University Hospital, Heidelberg, Germany; Institute of Psychiatry and Neurology, Warsaw, Poland).
If you are a newly diagnosed Wilson Disease patient you may be eligible to join the trial that is currently underway, if you meet the following criteria:
- Male or female, aged 18 years or older
- Have elevated blood free copper levels
- Treated with chelation or zinc therapy for 28 days or less
- Have hepatic or neurological symptoms or both
- In otherwise general good health
The study lasts for 7 months. There are 8 study visits to the study site during this 7 month period and 5 additional study visits with a potential for a nurse to visit you at home to reduce the amount of travel for you. Wilson Therapeutics will pay for your travel expenses.
For further information about this study, please go to: Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients or EU Clinical Trials Register To discuss possible participation at any of the United States study centers please contact the University of Michigan Hospital Wilson Disease Clinic by calling 1-800-333-9013. Contact details for all the individual sites are listed in the clinical trials links above.